Mechanistic insights into Radix Astragali for diabetes, hyperlipidemia, and hyperuricemia through medicine–food homology
10.1097/st9.0000000000000115
- Author:
Yue ZHAO
1
;
Henghui ZHANG
1
;
Haibin WANG
2
;
Luyao MA
2
;
Chimedragchaa CHIMEDTSEREN
3
;
Myadagbadam URTNASAN
3
;
Mengyang WANG
1
;
Wenping XIANG
4
;
Minhui LI
1
Author Information
1. Department of Pharmacy, Baotou Medical College, Baotou, China; Central Laboratory, Inner Mongolia Autonomous Region Hospital of Traditional Chinese Medicine, Hohhot, China
2. Central Laboratory, Inner Mongolia Autonomous Region Hospital of Traditional Chinese Medicine, Hohhot, China; Graduate School, Inner Mongolia Medical University, Hohhot, China
3. Institute of Traditional Medicine and Technology of Mongolia, Ulaanbaatar, Mongolia
4. Central Laboratory, Inner Mongolia Autonomous Region Hospital of Traditional Chinese Medicine, Hohhot, China; Baotou Mongolian and Traditional Chinese Medicine Hospital, Baotou, China
- Publication Type:Journal Article
- Keywords:
Chronic metabolic disease;
Diabetes;
Hyperlipidemia;
Hyperuricemia;
Medicine and food homology;
Radix Astragali
- From:
Science of Traditional Chinese Medicine
2026;4(3):244-254
- CountryChina
- Language:English
-
Abstract:
Diabetes, hyperlipidemia, and hyperuricemia have emerged as global chronic metabolic disorders posing significant public health challenges. Edible medicinal plants demonstrate multitarget regulatory effects and favorable safety profiles in the management of chronic metabolic diseases, owing to their bioactive compounds and nutritional synergy. Radix Astragali (RA), a traditional Chinese medicine with medicine–food homology, has a long history of application in China. Based on a review of relevant literature, this article discusses the historical background, modern research, therapeutic functions, and mechanisms of RA in the treatment of chronic metabolic diseases. Modern studies have shown that RA contains a variety of bioactive components and demonstrates efficacy in managing diabetes, hyperlipidemia, and hyperuricemia. Its mechanisms of action involve modulation of the insulin signaling pathway, regulation of lipid metabolism-related enzyme activity, promotion of uric acid excretion, and other processes. Notably, RA exhibits certain common therapeutic effects across hyperglycemia, hyperlipidemia, and hyperuricemia. Through modulation of the gut microbiota and inhibition of inflammatory pathways, RA exerts synergistic, multitarget effects that improve metabolic disorders associated with chronic metabolic diseases.
